



ASX ANNOUNCEMENT

5 October 2010

Appointment of Independent Commercialisation Consultant

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced the appointment of an independent consultant, Mr Geoff Morris, to assist in commercial partner negotiations for the use of VitroGro® in a new generation of acute and chronic wound healing products.

Mr Morris, who lives in the United States, is an exceptionally experienced former executive and now consultant in the healthcare industry, with a mixture of international large corporate and consulting achievements.

Mr Morris' international successes include establishing and growing global health care products, brands and businesses, many of these in the wound healing segment.

The Chairman of Tissue Therapies, Mr Roger Clarke said, "The Board of Tissue Therapies is particularly pleased to have the assistance of Mr Morris to advance our negotiations to a conclusion with a number of prospective commercialisation partner health care companies."

Mr Clarke went on to say, "Our objective is to establish an agreement with the health care partner that is best positioned to transform the wound care market with a new generation of VitroGro® products. We have confidence that the involvement of Mr Morris will optimise our position in these negotiations."

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell-based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com